Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Recurrence 1 Neoplasm, Residual 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Biphenotypic, Acute 1 Leukemia 1

Interventions

Cyclophosphamide 38 fludarabine 30 Rituximab 26 obinutuzumab 10 Bendamustine Hydrochloride 10 fludarabine phosphate 9 pembrolizumab 8 Specimen Handling 7 Etoposide 7 venetoclax 6 Vincristine 6 Prednisone 6 Magnetic Resonance Spectroscopy 6 Leukapheresis 6 Lenalidomide 6 ibrutinib 5 Inotuzumab Ozogamicin 5 Immunotherapy, Adoptive 5 Doxorubicin 5 Biopsy 5 ublituximab 4 tazemetostat 4 glofitamab 4 Interleukin-2 4 Dexamethasone 4 Cytarabine 4 pomalidomide 3 polatuzumab vedotin 3 Radiation 3 Nivolumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lymphoma, B-Cell × tisagenlecleucel × Clear all

NCT04419909 2025-07-02

Retreatment With CTL019/CTL119

University of Pennsylvania

Phase 1 Not yet recruiting

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡